Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Benjamin J. Zeskind, President and CEO of Immuneering Corp (NASDAQ:IMRX), recently purchased 21,000 shares of Class A Common Stock. According to a Form 4 filing with the Securities and Exchange Commission, the transaction occurred on June 18, 2025. The timing appears strategic, as InvestingPro data shows the stock has surged 45.79% in the past week, with the current price at $2.77.
The shares were bought at a weighted average price of $2.3878, with individual prices ranging from $2.31 to $2.44, totaling $50,143. Following the transaction, Zeskind directly owns 2,302,852 shares of Immuneering. According to InvestingPro analysis, the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 7.48.
Additionally, Zeskind indirectly owns 894,927 shares through the Benjamin J. Zeskind 2020 Family Trust, for which Lisa Schwartz, Zeskind’s spouse, serves as the sole trustee.
In other recent news, Immuneering Corporation announced positive interim results from its Phase 2a clinical trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer treatment. The trial demonstrated a 94% overall survival rate and a 72% progression-free survival rate at six months, surpassing standard care benchmarks. Mizuho (NYSE:MFG) responded by raising its price target for Immuneering to $10, maintaining an Outperform rating due to the drug’s promising data and favorable safety profile. Immuneering plans to increase target enrollment in the trial to approximately 50 patients and aims to initiate a pivotal trial in 2026. Additionally, the company appointed Dr. Igor Matushansky as its new Chief Medical (TASE:BLWV) Officer to lead its cancer drug programs. At the recent Annual Meeting of Stockholders, three Class I directors were elected, and RSM US LLP was ratified as the independent registered public accounting firm. These developments reflect Immuneering’s ongoing efforts to advance its cancer treatment pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.